Pfizer Statement Regarding Lyrica Epilepsy Study A0081047

The independent Data Monitoring Committee (DMC) for Lyrica epilepsy study A0081047 entitled “A Double-Blind, Randomized, Multicenter Efficacy and Safety Study of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures” has completed their review of the interim analysis. The DMC recommended that the study be stopped based on positive findings for the primary efficacy endpoint. This is according to the pre-specified criteria for evaluation of efficacy at the interim analysis for the study. Pfizer has accepted the DMC’s recommendation and has stopped the study. Additional details will be made public when the double-blind code for the study has been appropriately released for general analyses to be conducted. We are pleased to provide data for patients with epilepsy who could benefit from Lyrica monotherapy in clinical practice.

# # #